Xencor, Inc. (NASDAQ:XNCR) Receives $28.00 Average Price Target from Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $28.00.

Several analysts have weighed in on XNCR shares. Wedbush reiterated an "outperform" rating and set a $31.00 price target on shares of Xencor in a research note on Wednesday, April 30th. William Blair began coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock. Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen downgraded Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th.

Xencor Stock Performance

Xencor stock traded up $0.11 during trading hours on Thursday, hitting $8.41. 306,907 shares of the stock traded hands, compared to its average volume of 680,928. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 5.89. The firm's 50 day moving average price is $8.71 and its 200-day moving average price is $13.27. The stock has a market capitalization of $598.19 million, a price-to-earnings ratio of -2.75 and a beta of 0.85. Xencor has a 1 year low of $7.16 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The firm's revenue for the quarter was up 104.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.11) EPS. As a group, equities analysts expect that Xencor will post -3.68 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director owned 20,183 shares of the company's stock, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the transaction, the executive vice president directly owned 49,169 shares of the company's stock, valued at $542,334.07. The trade was a 8.58% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,810 shares of company stock worth $154,123. 4.76% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xencor

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC lifted its position in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares in the last quarter. New York State Teachers Retirement System lifted its position in shares of Xencor by 2.1% in the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock valued at $631,000 after acquiring an additional 1,200 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after acquiring an additional 1,282 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,337 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Xencor in the fourth quarter valued at approximately $34,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.